Evidence map›Paper›PMID 40132388›Full record

ArticleTranslational oncology2025

PIS as a regulator of cellular heterogeneity, prognostic significance, and immune landscape in thyroid cancer.

Xianjiang Wu, Lei Dai, Weidong Zhang, Qi Le, Yue Xie, Yingchun Wang

Abstract read
In one paragraph

Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xianjiang WuNingbo Second Hospital, Ningbo 315100, China.
Lei DaiNingbo Second Hospital, Ningbo 315100, China.
Weidong ZhangNingbo Second Hospital, Ningbo 315100, China.
Qi LeNingbo Second Hospital, Ningbo 315100, China.
Yue XieNingbo Second Hospital, Ningbo 315100, China.
Yingchun WangNingbo Second Hospital, Ningbo 315100, China. Electronic address: 475145514@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer (THCA) is a common endocrine malignancy with diverse clinical outcomes and tumor characteristics. In this study, we used single-cell RNA sequencing (scRNA-seq) to explore the cellular makeup and gene expression patterns of THCA. We identified distinct tumor subpopulations with varying differentiation and immune evasion properties. Our analysis revealed how tumor progression is influenced by dynamic gene expression changes over time. We also observed differences in immune cell infiltration across tumor subpopulations, with some showing immune-suppressive traits. A prognostic model, based on genes from a specific tumor subpopulation (RGS5+), outperformed existing models in predicting patient outcomes. Additionally, we found that high PIS (prognostic immune score) was linked to genetic instability, including increased tumor mutations and copy number variations. Key biological pathways associated with different tumor subpopulations were also identified, suggesting potential therapeutic targets. Finally, our analysis indicated that PIS could help predict responses to immunotherapy, with higher scores correlating with poorer treatment outcomes. Our findings highlight the complexity of THCA and emphasize the importance of considering tumor heterogeneity in personalized treatment strategies.

Indexed as

Immune microenvironmentPrognostic modelSingle-cell RNA sequencingThyroid cancerTumor heterogeneity

Identifiers

PMID40132388
PMCPMC11985066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.